Gilead trades that made millions on COVID-19 drug news raise eyebrows Posted on 1 Jun 2020 By Peter In News Well-timed trades in Gilead Sciences Inc’s options ahead of good news on the biopharmaceutical company’s COVID-19 drug treatment may draw regulatory scrutiny, experts said. Written by Peter Peter Zirbes, ESQ. A Full Service Law Office 718 544 6300 ← →